Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

23 Mar 2022

• By Jessica Merrill

foundation — Novartis is laying a commercial foundation in prostate cancer • Source: Alamy

Related Content

AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership

05 Jul 2018

Novartis Broadens VISION On Radioligands

07 Jun 2021

Bayer Back In Radiopharmaceuticals Ring With Noria Buy

04 Jun 2021

Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

02 Dec 2021

Related Companies

Novartis AG

Advanced Accelerator Applications SA

Bayer AG

Johnson & Johnson

Additional Topics

Launches Commercial Business Strategies Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.